Comparing Jakafi vs Rinvoq

View side-by-side comparisons of medication uses, ratings, cost, side effects and interactions.
Jakafi (ruxolitinib)	Rinvoq (upadacitinib)	Enter another drug to compare

Jakafi (ruxolitinib)

Rinvoq (upadacitinib)

Prescription only

Prescribed for Polycythemia Vera, Myelofibrosis, Myeloproliferative Disorders, Graft Versus Host Disease. Jakafi may also be used for purposes not listed in this medication guide.

Prescription only

Prescribed for Crohn's Disease, Ankylosing Spondylitis, Atopic Dermatitis, Non-Radiographic Axial Spondyloarthritis, Giant Cell Arteritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic... View more

More about Jakafi (ruxolitinib)

More about Rinvoq (upadacitinib)

Ratings & Reviews

Jakafi has an average rating of 7.5 out of 10 from a total of 33 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 15% reported a negative effect.

Rinvoq has an average rating of 7.1 out of 10 from a total of 234 ratings on Drugs.com. 56% of reviewers reported a positive effect, while 17% reported a negative effect.

View all 33 reviews

View all 234 reviews

Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified.

View all Jakafi side effects

Acne (9.8%)
Dizziness (7.7%)
Fatigue (6.8%)
Nausea (6.8%)
Headaches (6.0%)
Shortness of breath (5.1%)
Swelling (5.1%)

View all Rinvoq side effects

Drug Class

Multikinase inhibitors

Antirheumatics

Generic Availability

No lower cost generic approved

Pricing and Coupons * Prices are without insurance

Quantity	60 tablet
Strength	5 mg
Per unit^*	$313.31
Cost^*	$18,798.35

View all Jakafi prices

Quantity	30 tablet, extended release
Strength	15 mg
Per unit^*	$240.62
Cost^*	$7,218.71

View all Rinvoq prices

Get free Discount Card

Dosage Forms

Oral tablet

Oral tablet, extended release

Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value.

5.8 hours

14 hours

CSA Schedule ¹ View glossary of CSA terms

Not a controlled drug

Is not subject to the Controlled Substances Act.

Not a controlled drug

Is not subject to the Controlled Substances Act.

Pregnancy Category

Category C Risk cannot be ruled out

See the full pregnancy warnings document.

Summary unavailable.

See the full pregnancy warnings document.

Drug Interactions

A total of 512 drugs are known to interact with Jakafi:

137 major drug interactions (518 brand and generic names)
314 moderate drug interactions (1002 brand and generic names)
61 minor drug interactions (188 brand and generic names)

A total of 613 drugs are known to interact with Rinvoq:

380 major drug interactions (1255 brand and generic names)
223 moderate drug interactions (885 brand and generic names)
10 minor drug interactions (40 brand and generic names)

Alcohol/Food/Lifestyle Interactions

Do not consume grapefruit or grapefruit juice during treatment with ruxolitinib unless directed... View more

Consumption of grapefruit, grapefruit juice, and supplements that contain grapefruit should be... View more

Disease Interactions

First Approval Date

November 16, 2011

August 16, 2019

WADA Class View classifications

N/A

More Information

Patient Resources

Jakafi uses

Rinvoq uses

Professional Resources

N/A

¹ The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Comparing Jakafi vs Rinvoq

See also:

Besremi

Alecensa

Entyvio

Alunbrig

Augtyro

Ayvakit

Balversa

Braftovi

Cabometyx

Caprelsa

Further information

Comparing Jakafi vs Rinvoq

See also:

Further information

Compare Drugs